GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Intrinsic Value: Projected FCF

Clarity Pharmaceuticals (Clarity Pharmaceuticals) Intrinsic Value: Projected FCF : $0.00 (As of May. 24, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-24), Clarity Pharmaceuticals's Intrinsic Value: Projected FCF is $0.00. The stock price of Clarity Pharmaceuticals is $2.90. Therefore, Clarity Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Clarity Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:

CLRPF's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.3
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Clarity Pharmaceuticals Intrinsic Value: Projected FCF Historical Data

The historical data trend for Clarity Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Intrinsic Value: Projected FCF Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23
Intrinsic Value: Projected FCF
- -

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial - - - - -

Competitive Comparison of Clarity Pharmaceuticals's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Clarity Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarity Pharmaceuticals's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Price-to-Projected-FCF falls into.



Clarity Pharmaceuticals Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Clarity Pharmaceuticals  (OTCPK:CLRPF) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Clarity Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=2.90/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarity Pharmaceuticals Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.